Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953938 | 0.87 | HSD17B1 (0.54) | KMT2AMEN1ALDH1A1HTTMAPT | |
| SCHEMBL3790236 | 0.81 | MAPT (0.47) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1676565 | 0.81 | GAA (0.45) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL6579496 | 0.78 | SMN1; SMN2 (0.66) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL29451289 | 0.78 | SMN1; SMN2 (0.66) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL10534559 | 0.78 | PYGL (0.57) | KMT2AMEN1ALDH1A1HTTKDM4E | |
| SCHEMBL15279864 | 0.78 | ALDH1A1 (0.52) | KMT2AMEN1ALDH1A1HTTMAPT | |
| SCHEMBL2088259 | 0.78 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1HTTKDM4E | |
| SCHEMBL2502603 | 0.78 | MAPT (0.71) | KMT2AMEN1ALDH1A1HTTKDM4E | |
| SCHEMBL5658638 | 0.77 | KMT2A (0.53) | KMT2AMEN1ALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7538252-B2 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | BIPAR SCIENCES, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291924-A1 | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof | TUBB, TUBA1C, TUBB1 | KMT2A 3530/4885MEN1 3420/4885ALDH1A1 3322/4885 |
| US-20080076737-A1 | DRUG DESIGN FOR TUBULIN INHIBITORS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | TUBB, TUBA1C, TUBB1 | KMT2A 3530/4885MEN1 3420/4885ALDH1A1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.